These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1878109)

  • 1. Synthesis and biological behavior of a boronated analogue of the antiestrogen U 23,469-M.
    Wellmann F; Abraham R; Müller R; Gabel D
    Z Naturforsch C J Biosci; 1991; 46(3-4):252-6. PubMed ID: 1878109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor-targeted liposomal delivery of boron-containing cholesterol mimics for boron neutron capture therapy (BNCT).
    Thirumamagal BT; Zhao XB; Bandyopadhyaya AK; Naranyanasamy S; Johnsamuel J; Tiwari R; Golightly DW; Patel V; Jehning BT; Backer MV; Barth RF; Lee RJ; Backer JM; Tjarks W
    Bioconjug Chem; 2006; 17(5):1141-50. PubMed ID: 16984121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells.
    Miller MA; Lippman ME; Katzenellenbogen BS
    Cancer Res; 1984 Nov; 44(11):5038-45. PubMed ID: 6488162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New estrogenic antagonists bearing dicarba-closo-dodecaborane as a hydrophobic pharmacophore.
    Endo Y; Yoshimi T; Yamakoshi Y
    Chem Pharm Bull (Tokyo); 2000 Feb; 48(2):312-4. PubMed ID: 10705532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and evaluation of a boronated nitroimidazole for boron neutron capture therapy.
    Swenson DH; Laster BH; Metzger RL
    J Med Chem; 1996 Mar; 39(7):1540-4. PubMed ID: 8691485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of boronated nucleosides for boron neutron capture therapy (BNCT) of cancer.
    Tjarks W; Wang J; Chandra S; Ji W; Zhuo J; Lunato AJ; Boyer C; Li Q; Usova EV; Eriksson S; Morrison GH; Cosquer GY
    Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):695-8. PubMed ID: 11563094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological efficacy of boronated low-density lipoprotein for boron neutron capture therapy as measured in cell culture.
    Laster BH; Kahl SB; Popenoe EA; Pate DW; Fairchild RG
    Cancer Res; 1991 Sep; 51(17):4588-93. PubMed ID: 1873803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Boronated thymidine analogues for boron neutron capture therapy.
    Thirumamagal BT; Johnsamuel J; Cosquer GY; Byun Y; Yan J; Narayanasamy S; Tjarks W; Barth RF; Al-Madhoun AS; Eriksson S
    Nucleosides Nucleotides Nucleic Acids; 2006; 25(8):861-6. PubMed ID: 16901817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiestrogen action in breast cancer cells: modulation of proliferation and protein synthesis, and interaction with estrogen receptors and additional antiestrogen binding sites.
    Katzenellenbogen BS; Miller MA; Mullick A; Sheen YY
    Breast Cancer Res Treat; 1985; 5(3):231-43. PubMed ID: 4027393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICI 164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells.
    Poulin R; Merand Y; Poirier D; Levesque C; Dufour JM; Labrie F
    Breast Cancer Res Treat; 1989 Oct; 14(1):65-76. PubMed ID: 2605344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential regulation by estrogens of growth and prolactin synthesis in pituitary cells suggests that only a small pool of estrogen receptors is required for growth.
    Chun TY; Gregg D; Sarkar DK; Gorski J
    Proc Natl Acad Sci U S A; 1998 Mar; 95(5):2325-30. PubMed ID: 9482884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiestrogens and antiestrogen metabolites: preparation of tritium-labeled (+/-)-cis-3-[p-(1,2,3,4-tetrahydro-6-methoxy-2-phenyl-1-naphthyl)phenoxyl]-1,2-propanediol (U-23469) and characterization and synthesis of a biologically important metabolite.
    Tatee T; Carlson KE; Katzenellenbogen JA; Robertson DW; Katzenellenbogen BS
    J Med Chem; 1979 Dec; 22(12):1509-17. PubMed ID: 536996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethyl side-chain modifications in novel flexible antiestrogens--design, synthesis and biological efficacy in assay against the MCF-7 breast tumor cell line.
    Meegan MJ; Hughes RB; Lloyd DG; Williams DC; Zisterer DM
    Anticancer Drug Des; 2001 Feb; 16(1):57-69. PubMed ID: 11762645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steroidal affinity labels of the estrogen receptor. 3. Estradiol 11 beta-n-alkyl derivatives bearing a terminal electrophilic group: antiestrogenic and cytotoxic properties.
    Lobaccaro C; Pons JF; Duchesne MJ; Auzou G; Pons M; Nique F; Teutsch G; Borgna JL
    J Med Chem; 1997 Jul; 40(14):2217-27. PubMed ID: 9216841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo and in vitro effects of boron and boronated compounds.
    Benderdour M; Bui-Van T; Dicko A; Belleville F
    J Trace Elem Med Biol; 1998 Mar; 12(1):2-7. PubMed ID: 9638606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of boron clusters for drug design. Relation between estrogen receptor binding affinity and hydrophobicity of phenols bearing various types of carboranyl groups.
    Endo Y; Yamamoto K; Kagechika H
    Bioorg Med Chem Lett; 2003 Nov; 13(22):4089-92. PubMed ID: 14592514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enantioselective synthesis and biological evaluation of 5-o-carboranyl pyrimidine nucleosides.
    Mourier NS; Eleuteri A; Hurwitz SJ; Tharnish PM; Schinazi RF
    Bioorg Med Chem; 1999 Dec; 7(12):2759-66. PubMed ID: 10658581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation of a new carboranyl lactoside for the treatment of cancer by boron neutron capture therapy: synthesis and toxicity of fluoro carboranyl glycosides for in vivo 19F-NMR spectroscopy.
    Tietze LF; Bothe U; Schuberth I
    Chemistry; 2000 Mar; 6(5):836-42. PubMed ID: 10826605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dissociation rate of estrogen receptor-ligand complexes is increased by high concentrations of steroids and antiestrogens.
    Borgna JL; Ladrech S
    Mol Cell Endocrinol; 1982 Jun; 27(1):1-15. PubMed ID: 7106368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiestrogen pharmacology and mechanism of action.
    Katzenellenbogen BS; Miller MA; Eckert RL; Sudo K
    J Steroid Biochem; 1983 Jul; 19(1A):59-68. PubMed ID: 6887873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.